Skip to main content
. 2022 Jan 18;28(7):1402–1411. doi: 10.1158/1078-0432.CCR-21-3752

Figure 4.

Figure 4. Clinical benefit. Boxplot showing clinical benefit (CB; yes or no) per drug type and involved pathway in absolute numbers (n; upper figure) and percentage (%; bottom figure) of rare cancers (A) and nonrare cancers (B). i, inhibitor; NE, not evaluable.

Clinical benefit. Boxplot showing clinical benefit (CB; yes or no) per drug type and involved pathway in absolute numbers (n; upper figure) and percentage (%; bottom figure) of rare cancers (A) and nonrare cancers (B). i, inhibitor; NE, not evaluable.